Table 5.

Future areas of investigation for mitigating cardiovascular risk in patients with cancer.

Areas of future investigation in the management of hyperlipidemia and CV risk reduction in patients with cancer
1. What is the best CV risk assessment tool to identify those patients with cancer who are at an elevated risk for developing late CVD?
2. What is the role of coronary artery calcium scoring in the CV risk stratification of patients with cancer?
3. What is the utility of serum markers (lipoprotein(a), apolipoprotein B, high sensitivity CRP) in these patients?
4. What is the role of non-statin therapies, including ezetimibe, PCSK9 inhibitors, bempedoic acid and icosapent ethyl, in the management of dyslipidemia in cancer patients?